A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

A method was developed to visualize dye extravasation due to blood-brain barrier (BBB) breakdown by administering two fluorescent dyes to mice at different time points. The use of glycerol as a cryoprotectant facilitated immunohistochemistry on the same sample.

Abstract

Fluorescent dyes are used to determine the extent of dye extravasation that occurs due to blood-brain barrier (BBB) breakdown. Labeling with these dyes is a complex process influenced by several factors, such as the concentration of dyes in the blood, permeability of brain vessels, duration of dye extravasation, and reduction in dye concentration in the tissue due to degradation and diffusion. In a mild traumatic brain injury model, exposure to blast-induced shock waves (BSWs) triggers BBB breakdown within a limited time window. To determine the precise sequence of BBB breakdown, Evans blue, and fluorescein isothiocyanate-dextran were injected intravascularly and intracardially into mice at various time points relative to BSW exposure. The distribution of dye fluorescence in brain slices was then recorded. Differences in the distribution and intensity between the two dyes revealed the spatiotemporal sequence of BBB breakdown. Immunostaining of the brain slices showed that astrocytic and microglial responses correlated with the sites of BBB breakdown. This protocol has broad potential for application in studies involving different BBB breakdown models.

Introduction

Blood-brain barrier (BBB) breakdown and dysfunction are caused by systemic inflammation, infections, autoimmune diseases, injuries, and neurodegenerative diseases1. In mild traumatic brain injury (mTBI) resulting from exposure to blast-induced shock waves (BSWs), a significant correlation has been observed between the intensity of BSWs and the amount of fluorescent dye leakage due to BBB breakdown2,3,4. One notable feature of BBB breakdown in mTBI is that it begins immediately or within a few hours after exposure to BSWs and is usually a transient process that lasts for about a week before delayed, chronic neurological disorders emerge3,5,6,7. Although the details remain unclear, BBB breakdown is part of the long-lasting pathological cascade and may also serve as a prognostic factor in mTBI6. Therefore, understanding the spatial and temporal distributions of BBB breakdown in the brain is important.

Fluorescent dyes are used to determine the extent of BBB breakdown3,8. Because the blood concentration of the dyes and the magnitude and extent of BBB breakdown change over time, caution is required when interpreting images of dye extravasation. For instance, the absence of dye extravasation does not necessarily indicate the absence of BBB breakdown. No BBB breakdown may be detected before or after an increase in the dye's blood concentration. Even if the dye successfully accumulated where BBB breakdown occurred, it may have been lost over time after the breakdown ceased. In general, water-soluble and biologically inert substances are quickly excreted in the urine9. Therefore, to determine whether BBB breakdown occurs at a specific time, the most reliable results are obtained when a fluorescent dye is administered into the bloodstream for a short period immediately before fixing the animal. Commercially available fluorescein isothiocyanate (FITC)-dextran with a specific molecular weight should be used in this manner.

Evans blue is a widely recognized blue azo dye with a strong affinity for serum albumin. The dye exhibits red fluorescence when excited by green light in biological systems2. Due to its inert nature, the Evans blue-serum albumin complex remains in the blood for up to 2 h, making it a useful 69 kDa tracer for labeling regions with a compromised BBB for at least this duration10,11. Therefore, it is important to consider potential uncertainties surrounding the pharmacokinetics and toxicity of Evans blue9. However, a recent study showed that Evans blue continues to accumulate in areas where the BBB is absent or disrupted7. This feature enabled Evans Blue to record the history of the BBB breakdown, while FITC-dextran was used to record the BBB breakdown at a specific time point after the BSW exposure. Although Evans blue can be administered intravenously or intraperitoneally10, intravenous administration is preferred for time-sensitive experiments. This study aimed to demonstrate the use of Evans blue and FITC-dextran to detect the spatiotemporal distribution of BBB breakdown following exposure to BSW.

Second, the study presented a technique for freezing brain slices after observing the fluorescence of BBB breakdown and preparing thinner slices suitable for immunohistochemical procedures. The use of glycerol as a mounting medium and cryoprotectant simplifies the immunohistochemistry process. By comparing images of BBB breakdown with those from immunohistochemistry, the spatiotemporal distribution of BBB breakdown can be correlated with the tissue response of the same sample.

Protocol

All experiments were conducted in accordance with the ethical guidelines for animal experiments established by the National Defense Medical College (Tokorozawa, Japan). The study protocol was approved by the Committee for Animal Research at the National Defense Medical College (approval no. 23011-1). Male C57BL/6J mice aged 8 weeks and weighing 19-23 g were used in this study. Details of the reagents and equipment used are listed in the Table of Materials.

1. Animal preparation

NOTE: This is a modified protocol that increases the amount of medetomidine by 2.5 times compared with the original one12. The dosages for medetomidine hydrochloride, midazolam, and butorphanol were 0.75 mg/kg, 4 mg/kg, and 5 mg/kg, respectively.

  1. Prepare a mixture of medetomidine hydrochloride (75 Β΅g/mL), midazolam (400 Β΅g/mL), and butorphanol (500 Β΅g/mL) in physiological saline.
  2. Administer the mixture intraperitoneally to anesthetize the mouse (10 Β΅L/g)13.
  3. After approximately 5-10 min, verify sufficient anesthesia by observing the lack of tail pinch and pedal withdrawal reflexes.
  4. Keep the mouse warm until it recovers from the effects of anesthesia.

2. BSW exposure

NOTE: An in-house shock tube was used in this study14.

  1. Anesthetize the mouse as described in step 1.
  2. Position the mouse 5 cm away from the exit end of the shock tube, ensuring its body axis is parallel to but not aligned with the tube's axis.
  3. Deliver a single BSW exposure with a peak overpressure of 25 kPa to the head.

3. Evans blue injection into the tail vein

NOTE: Evans blue solution should be administered intravenously without anesthesia. In the presence of anesthesia, the dye often does not penetrate the body sufficiently, likely due to decreased blood pressure and body temperature13. Evans blue was administered at a dose of 100 mg/kg.

  1. Prepare the Evans blue solution (4% w/v in saline) in a microtube, then vortex and store it in the dark before use.
  2. Inject the solution into the tail vein (2.5 Β΅L/g)13.

4. Transcardial perfusion with FITC-dextran solution and fixation

  1. Add heparin to phosphate-buffered saline (PBS) to obtain a concentration of 1 U/mL, then add FITC-dextran to the heparinized PBS to achieve a concentration of 3 mg/mL.
  2. Completely dissolve the FITC-dextran powder before use. To do this, gently shake the solution for 30 min or more. Before use, carefully check for any undissolved FITC-dextran powder. If any remains, continue shaking until it is completely dissolved.
  3. Anesthetize the mouse as described in step 1.
  4. Proceed with the standard perfusion fixation protocol using a peristaltic pump15,16. First, perfuse with heparinized PBS containing FITC-dextran for 2 min at a rate of 4.0 mL/min. Then, perfuse with 10% formalin neutral buffer solution or 4% paraformaldehyde-PBS for 2 min at a rate of 4.0 mL/min, followed by 8 min at a rate of 3.5 mL/min.
  5. Carefully remove the brain using surgical scissors and tweezers15,16. After dissection, post-fix the brain overnight in the same fixative (i.e., 10% formalin neutral buffer solution or 4% paraformaldehyde-PBS) at 4 Β°C.
  6. On the following day, replace the fixative with PBS.

5. Brain tissue processing

NOTE: Even if perfusion fixation is complete, Evans blue and FITC-dextran may disperse into the buffer. Therefore, the procedures leading up to step 6.8 should be completed within a week after perfusion fixation. Additionally, avoid exposing the sample to light.

  1. Prepare a 24-well plate with 500 Β΅L of 20% glycerol in phosphate buffer (PB; pH 7.4) in each well.
  2. Using a brain slicer, cut the brain coronally into 12 slices, each 1 mm thick.
  3. Transfer each slice into the corresponding well of the 24-well plate and store it at 4 Β°C for at least 2 h.
  4. Replace the solution with 50% glycerol-PB and store it at 4 Β°C for at least 2 h.
  5. Finally, replace the solution with 100% glycerol. For immediate microscopic observation, allow the slices to stand for at least 2 h at room temperature or store them at 4 Β°C. The slices will now be translucent and ready for microscopic observation.

6. Fluorescence measurement of dye extravasation

NOTE: Fluorescence labeling efficiency varies from mouse to mouse. Therefore, fluorescence intensity needs to be normalized. Fluorescence values are expressed relative to those within the gigantocellular reticular nucleus (GRN) because this region is minimally affected by BSW treatment.

  1. Add 500 Β΅L of glycerol to the bottom of a 35-mm glass-bottom dish.
  2. Transfer the slice to the glycerol solution and cover its surface with a coverglass.
  3. Remove excess glycerol from the edge of the coverglass.
  4. Measure the fluorescence intensity of the slice under a fluorescence microscope.
  5. After microscopic measurement, return the slice to the well.
  6. Repeat the measurement for all 12 slices.
  7. Add 500 Β΅L of PB to each well and store the 24-well plate at 4 Β°C overnight; on the following day, the slices will be saturated with 50% glycerol-PB.
  8. Replace the solution with 30% glycerol-PB and store it at 4 Β°C for at least 2 h.
  9. Perform the procedures in step 7 within a few weeks.

7. Cryosectioning and immunohistochemistry

  1. Prepare a 24-well plate by adding 1000 Β΅L of a mixture of equal volumes of tissue freezing medium and 30% glycerol-PB to well 1. Then, add 1000 Β΅L of tissue freezing medium to well 2.
  2. Transfer the slice to well 1 and shake the plate at 4 Β°C for 1 h.
  3. Transfer the slice to well 2 and shake the plate at 4 Β°C for 1 h.
  4. Quickly freeze the slice with isopentane using dry ice, taking care not to bend the slice. Store the slices at -80 Β°C until cryosectioning.
  5. Cryosection the slice to a thickness of 6 Β΅m. After drying on the microscope slide, store the sections at -80 Β°C.
  6. For antigen retrieval17, immerse the sections in 10 mM sodium citrate (pH 6.0), heat to 100 Β°C once, and then maintain at 98 Β°C for 1 h.
  7. Wash the sections extensively in distilled water. The sections are now ready for immunohistochemical staining.

Results

Figure 1A shows the time course of dye injection in relation to the onset of BSW, with a peak overpressure of 25 kPa. In the 'Post' protocol, Evans blue solution was administered intravascularly 2 h before FITC-dextran perfusion, which was conducted 6 h, 1 day, 3 days, and 7 days after BSW exposure. In the 'Pre' protocol, Evans blue solution was injected immediately before BSW exposure. In the 'Post' protocol, the concentration of Evans blue is expected to reach its m...

Discussion

A novel double-labeling technique using Evans blue and FITC-dextran was used to accurately visualize the precise spatiotemporal distribution of BBB breakdown in a single brain. In the low-intensity BSW model, noticeable variations in the extent, location, and degree of dye extravasation were observed in examined brains (Figure 2 and Figure 3). Between-dye mismatches revealed that BBB breakdown commenced approximately 3 h after BSW exposure, with substantial remo...

Disclosures

The authors have nothing to disclose.

Acknowledgements

We thank Mayumi Watanabe for the cryosectioning technique. This work was supported by an Advanced Research on Military Medicine grant from the Ministry of Defense, Japan.

Materials

NameCompanyCatalog NumberComments
10% Formalin Neutral Buffer SolutionFUJIFILM Wako Chemicals062-01661
Anti GFAP, RabbitDAKO-AgilentIR524
Anti Iba1, RabbitFUJIFILM Wako Chemicals019-19741
Chicken anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488Thermo Fisher ScientificA-21200
Cryo MountMuto Pure Chemicals33351tissue freezing medium
DomitorOrion Corporationmedetomidine
Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 546Thermo Fisher ScientificA10040
Evans BlueSigma-AldrichΒ E2129
Falcon 24-well Polystyrene Clear Flat Bottom Not Treated Cell Culture Plate, with Lid, Individually Wrapped, Sterile, 50/CaseCORNING351147
Fluorescein isothiocyanate–dextran average mol wt 40,000Sigma-AldrichΒ FD40SFITC-dextran
Glass Base Dish 27mm (No.1 Glass)AGC TECHNO GLASS3910-03535 mm glass bottom dish
IX83 Inverted MicroscopeOLYMPUS
MAS Hydrophilic Adhesion Microscope SlidesMatsunami GlassMAS-04
MatsunamiΒ Cover Glass (No.1)Β 18 x 18mmMatsunami GlassC018181
Midazolam Injection 10mg [SANDOZ]Sandoz
Paraformaldehyde EMPROVE ESSENTIAL DACMerck Millipore1.04005.1000
Peristaltic PumpATTOSJ-1211 II-H
RODENT BRAIN MATRIX
Adult Mouse, 30 g, Coronal
ASI INSTRUMENTSRBM-2000Cbrain slicer
VetorphaleMeiji Animal HealthVETLI5butorphanol

References

  1. Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., Zlokovic, B. V. Blood-brain barrier: From physiology to disease and back. Physiol Rev. 99 (1), 21-78 (2019).
  2. Kabu, S., et al. Blast-associated shock waves result in increased brain vascular leakage and elevated ros levels in a rat model of traumatic brain injury. PLoS One. 10 (5), e0127971 (2015).
  3. Kuriakose, M., Rama Rao, K. V., Younger, D., Chandra, N. Temporal and spatial effects of blast overpressure on blood-brain barrier permeability in traumatic brain injury. Sci Rep. 8 (1), 8681 (2018).
  4. Yeoh, S., Bell, E. D., Monson, K. L. Distribution of blood-brain barrier disruption in primary blast injury. Ann Biomed Eng. 41 (10), 2206-2214 (2013).
  5. Readnower, R. D., et al. Increase in blood-brain barrier permeability, oxidative stress, and activated microglia in a rat model of blast-induced traumatic brain injury. J Neurosci Res. 88 (16), 3530-3539 (2010).
  6. Shetty, A. K., Mishra, V., Kodali, M., Hattiangady, B. Blood-brain barrier dysfunction and delayed neurological deficits in mild traumatic brain injury induced by blast shock waves. Front Cell Neurosci. 8, 232 (2014).
  7. Nishii, K., et al. Evans blue and fluorescein isothiocyanate-dextran double labeling reveals the precise sequence of vascular leakage and glial responses after exposure to mild-level blast-associated shock waves. J Neurotrauma. 40 (11-12), 1228-1242 (2023).
  8. Hoffmann, A., et al. High and low molecular weight fluorescein isothiocyanate (FITC)-dextrans to assess blood-brain barrier disruption: Technical considerations. Transl Stroke Res. 2 (1), 106-111 (2011).
  9. Saunders, N. R., Dziegielewska, K. M., MΓΈllgΓ₯rd, K., Habgood, M. D. Markers for blood-brain barrier integrity: How appropriate is Evans blue in the twenty-first century and what are the alternatives. Front Neurosci. 9, 385 (2015).
  10. Manaenko, A., Chen, H., Kammer, J., Zhang, J. H., Tang, J. Comparison Evans blue injection routes: Intravenous versus intraperitoneal, for measurement of blood-brain barrier in a mice hemorrhage model. J Neurosci Methods. 195 (2), 206-210 (2011).
  11. Yen, L. F., Wei, V. C., Kuo, E. Y., Lai, T. W. Distinct patterns of cerebral extravasation by Evans blue and sodium fluorescein in rats. PLoS One. 8 (7), e68595 (2013).
  12. Kawai, S., Takagi, Y., Kaneko, S., Kurosawa, T. Effect of three types of mixed anesthetic agents alternate to ketamine in mice. Exp Anim. 60 (5), 481-487 (2011).
  13. Machholz, E., Mulder, G., Ruiz, C., Corning, B. F., Pritchett-Corning, K. R. Manual restraint and common compound administration routes in mice and rats. J Vis Exp. 67, e2771 (2012).
  14. Satoh, Y., et al. Molecular hydrogen prevents social deficits and depression-like behaviors induced by low-intensity blast in mice. J Neuropathol Exp Neurol. 77 (9), 827-836 (2018).
  15. Gage, G. J., Kipke, D. R., Shain, W. Whole animal perfusion fixation for rodents. J Vis Exp. 65, e3564 (2012).
  16. Selever, J., Kong, J. Q., Arenkiel, B. R. A rapid approach to high-resolution fluorescence imaging in semi-thick brain slices. J Vis Exp. 53, e2807 (2011).
  17. Jiao, Y., et al. A simple and sensitive antigen retrieval method for free-floating and slide-mounted tissue sections. J Neurosci Methods. 93 (2), 149-162 (1999).
  18. Nagaraja, T. N., Keenan, K. A., Fenstermacher, J. D., Knight, R. A. Acute leakage patterns of fluorescent plasma flow markers after transient focal cerebral ischemia suggest large openings in blood-brain barrier. Microcirculation. 15 (1), 1-14 (2010).
  19. Xu, Y., et al. Quantifying blood-brain-barrier leakage using a combination of Evans blue and high molecular weight fitc-dextran. J Neurosci Methods. 325, 108349 (2019).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

Neuroscience

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright Β© 2025 MyJoVE Corporation. All rights reserved